CAR DETECTION & CHARACTERIZATION
Connect CAR expression with target recognition by flow cytometry
Build a more complete picture of cells expressing a chimeric antigen receptor (CAR). Conigen’s novel cell surface antigen-based fusion proteins help you measure target-specific binding alongside CAR surface expression by flow cytometry.
For CAR construct design and screening, cell characterization, and assay development.
CONSTRUCT COMPARISON: CD19
Similar CAR expression.
Different target binding.
% anti-linker CAR expression cells
% CD19 specific CAR-binding cells
Conigen construct-comparison data. Explore all three measurements.
THREE MEASUREMENTS. THREE QUESTIONS.
CAR expression alone
does not tell the whole story.
Two constructs can look equivalent by anti-linker CAR staining. Adding target-specific binding is critical to reveal how they differ and their potential function.
01 / EXPRESSION
Is the CAR present on the cell?
Anti-linker or anti-tag staining identifies cells expressing the CAR construct.
CAR-positive cells
02 / TARGET RECOGNITION
Can the CAR bind its intended target?
A recombinant target antigen assesses the CAR’s binding to its intended target.
Target-binding cells
03 / FUNCTIONAL ACTIVITY
Does target recognition translate into functional activity?
A CAR T cell mediated tumor cell killing assay reveals the correlation between functional activity and target recognition.
Tumor-cell depletion
Antigen-Specific CAR Detection
CD20-ECL2 scaffold binding to the CAR is detected by anti-His APC, alongside anti-linker and anti-tag detection.
THE ANTIGEN–CAR INTERACTION
Make target recognition part of the picture.
In this example, the CD20 extracellular loop 2 (ECL2) scaffold binds the CAR. A fluorescent anti-His antibody detects the His-tag on the bound scaffold protein, while anti-linker or anti-tag staining measures CAR expression by flow cytometry.
Key components of an scFv-based CAR.
FDA GUIDANCE / JANUARY 2024
Direct detection and antigen recognition matter.
“Flow cytometry allows assessment of multiple CAR T cell attributes throughout the manufacturing process (e.g., cell viability, identity, purity, strength).”
“We recommend direct detection of the CAR to determine the percentage of CAR-positive cells. If the CAR is detected by surrogate protein expression (e.g., detection of a co-expressed gene) or other broad-specificity reagents (e.g., protein L), you should evaluate the correlation with CAR expression.”
“Nonclinical evaluation of the antigen recognition domain should include assessment of the specificity and affinity/avidity for the target antigen/cells to evaluate the potential for on-target/off -tumor and off-target toxicities.”
FDA, Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products. January 2024. This recommendation does not specify a particular detection reagent.
LET’S TALK ABOUT YOUR CAR
Your target.
Your construct.
A comprehensive measurement.
Developing a CAR construct or choosing a detection reagent? Tell us about your target, sample type, and staining workflow. We can help you explore available formats and supporting data.
THE EVIDENCE
See what expression
alone can miss.
Conigen used complementary measurements of CAR expression by anti-linker staining and antigen binding to compare CD19 CAR constructs. A tumor-cell killing assay provided an independent functional activity evaluation.
| Design change | Construct | % anti-linker CAR expression cells |
% CD19 specific CAR-binding cells |
Tumor-cell killing¹ |
|---|---|---|---|---|
| VH/VL orientation | A1 | 100% | 91% | 67% |
| A2 | 100% | 91% | 42% | |
| Leader sequence | B1 | 97% | 45% | 43% |
| B2 | 100% | 95% | 56% | |
| Intracellular domains | C1 | 87% | 60% | 48% |
| C2 | 100% | 97% | 63% |
¹ Effector-to-target ratio of 0.5:1.
B1 vs. B2
CAR expression looks similar. Antigen-binding reveals a difference.
CAR-positive staining is 97% versus 100%, while CD19 binding is 45% versus 95%. B2 also shows greater tumor-cell depletion: 56% versus 43%.
A1 & B1
Target recognition adds meaningful information.
A1 and B1 CAR constructs show similar high expression. A1 has greater CAR binding (91%) and tumor-cell killing (67%) while B1 has lower CAR binding (45%) and tumor-cell killing (43%).
A1 and A2 also have equal expression and binding but different depletion results—showing why functional testing remains a separate layer.
BUILT AROUND THE TARGET
Protein design shapes
what you can measure.
Target antigens need to preserve relevant binding sites. Conigen selects protein architectures for the structure of each target and evaluates binding to known antibodies or ligands.
CD19
An extracellular domain presented as a dimer.
A multivalent, Fc-free design presents the CD19 extracellular domain for target-specific CAR binding measurements.
CD19-specific CAR detection (anti-His-APC)
BCMA
A short extracellular domain
A different Fc-free scaffold supports presentation of BCMA’s shorter extracellular domain.
BCMA-specific CAR detection (anti-His-APC)
CD20
An extracellular loop
A scaffold presents CD20’s second extracellular loop, a region recognized by rituximab-based CARs.
CD20-specific CAR detection (anti-His-APC)
Choose a format for your staining workflow.
Depending on the target, available formats include His-tag, AviTag, and biotinylated protein reagents. Detection signal may use a fluorescently conjugated anti-His-tag or anti-AviTag, or a biotin-compatible signal readout by flow cytometry. Fc-free formats remove the FcR binding concern; protein format and assay suitability should be evaluated to fit your construct and sample.
EXPLORE YOUR RESEARCH AREA
Find the target.
Build the right assay.
Explore Conigen’s cell surface antigen-based fusion proteins in different disease and research areas. Linked targets open available product examples. These groups are a starting point: target expression and relevance can span several settings.
Questions?
Available formats and supporting data differ by target. Discuss your construct and detection needs with our team.
CAR-T RESOURCE HUB
Go deeper into
the approach and the data.
Explore practical explanations, application data, and scientific resources for your next assay.
Featured article
Rethinking CAR-T Cell Detection
See how measuring CAR expression and target-specific binding together adds information to construct characterization.
Read the article
Application note
Detecting Anti-CD19 CAR-T Cells
Explore CD19 dimer staining in primary T cells by flow cytometry.
See the application data
Detection approach
Antigen-Based CAR-T Detection
Learn about Fc-free antigen formats and explore available detection reagents.
Explore the approach
Scientific poster
Fc-Free CD19 Dimers for CAR-T Detection
Review the poster’s protein-design rationale and experimental results.
View the poster
Video overview
CD19 for Modern CAR-T Workflows
Get a quick introduction to CD19 proteins for detection and development assays.
Watch the overview
LET’S TALK ABOUT YOUR CAR
Your target.
Your construct.
A comprehensive measurement.
Developing a CAR construct or choosing a detection reagent? Tell us about your target, sample type, and staining workflow. We can help you explore available formats and supporting data.